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Although loss of the inhibitor of apoptosis (IAP) pro-
tein DIAP1 has been shown to result in caspase activa-
tion and spontaneous cell death in Drosophila cells and
embryos, the point at which DIAP1 normally functions
to inhibit caspase activation is unknown. Depletion of
the DIAP1 protein in Drosophila S2 cells or the Sf-IAP
protein in Spodoptera frugiperda Sf21 cells by RNA in-
terference (RNAi) or cycloheximide treatment resulted
in rapid and widespread caspase-dependent apoptosis.
Co-silencing of dronc or dark largely suppressed this
apoptosis, indicating that DIAP1 is normally required to
inhibit an activity dependent on these proteins. Silenc-
ing of dronc also inhibited DRICE processing following
stimulation of apoptosis, demonstrating that DRONC
functions as an apical caspase in S2 cells. Silencing of
diap1 or treatment with UV light induced DRONC proc-
essing, which occurred in two steps. The first step ap-
peared to occur continuously even in the absence of an
apoptotic signal and to be dependent on DARK, because
full-length DRONC accumulated when dark was silenced
in non-apoptotic cells. In addition, treatment with the
proteasome inhibitor MG132 resulted in accumulation of
this initially processed form of DRONC, but not full-
length DRONC, in non-apoptotic cells. The second step in
DRONC processing was observed only in apoptotic cells.
These results indicate that the initial step in DRONC
processing occurs continuously via a DARK-dependent
mechanism in Drosophila cells and that DIAP1 is re-
quired to prevent excess accumulation of this first form of
processed DRONC, presumably through its ability to act
as a ubiquitin-protein ligase.
The IAP1 proteins are conserved from yeast to humans and
are also found in certain viruses that infect invertebrates,
including baculoviruses and entomopoxviruses (1). IAP pro-
teins are identified by the presence of 1–3 copies of a motif
called a baculovirus IAP repeat (BIR) at the amino terminus.
Many IAP proteins also contain a RING finger motif at the
carboxyl terminus, some of which have been shown to possess
E3 activity (2). Most IAP proteins from insects and vertebrates
are capable of inhibiting apoptosis when overexpressed,
whereas IAP homologs in nematodes and yeast instead play a
role in regulating cytokinesis (1).
IAP proteins inhibit apoptosis stimulated by a variety of
signals in both insect and mammalian cells, presumably at
least in part through their ability to inhibit caspases, a family
of cysteine proteases that mediate many of the morphological
and biochemical changes associated with apoptosis (3). Follow-
ing a death signal, apical or signaling caspases become acti-
vated through proteolytic processing. These apical caspases in
turn proteolytically activate other caspases, called effector
caspases, that go on to cleave various target proteins, leading to
apoptosis (4). In mammalian cells, two major pathways leading
to apical caspase activation have been described, the extrinsic
and intrinsic pathways. The extrinsic pathway primarily in-
volves the activation of the apical caspases caspase-8 and -10
by death receptors such as fas and tumor necrosis factor recep-
tor, whereas the intrinsic pathway involves the release of fac-
tors from mitochondria such as cytochrome c that results in the
activation of apical caspase-9 via the Apaf-1 protein, an oli-
gomerizing factor required for the activation of caspase-9 in
mammals (5). Upon binding to cytochrome c, Apaf-1 forms
large oligomeric complexes known as apoptosomes that recruit
and activate caspase-9 (6, 7). In mammals, either caspase-8 or
-9 is capable of activating effector caspases such as caspase-3 or
-7, which then cleave apoptotic substrates, leading to apoptosis.
A link between the extrinsic and intrinsic pathways is observed
in certain cells that involves the cleavage of the Bcl-2 family
member Bid by caspase-8, which leads to release of cytochrome
c from mitochondria and activation of caspase-9 (8, 9).
Certain IAP proteins have been shown to inhibit both apical
and effector caspases, such as mammalian XIAP, where the
third BIR domain of XIAP directly binds and inhibits
caspase-9, whereas a short linker region between the first and
second BIR domains binds and inhibits caspases 3 and 7 (10).
Inhibition of caspase-9 is relieved by Smac/DIABLO, another
protein that is released from mitochondria following a death
signal and binds to BIR3 of XIAP, releasing caspase-9 (11, 12).
The Drosophila DIAP1 protein is also capable of inhibiting
death induced by ectopic caspase expression in yeast and in the
fly eye (13–15). This activity is important for the anti-apoptotic
function of DIAP1 because loss of DIAP1 results in caspase
activation and the death of most, if not all, cells in the embryo
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(15–18). In contrast, the xiap knockout mouse has no discern-
ible phenotype, although the levels of c-IAP1 and c-IAP2 were
higher than normal in embryonic fibroblasts derived from
XIAP-deficient mice, suggesting compensation because of the
loss of XIAP (19).
In Drosophila, a pathway similar to the intrinsic pathway in
mammals is beginning to be characterized (for a recent review
see Ref. 20). A protein with homology to Apaf-1, known as
DARK, Hac-1, or Dapaf-1 (21–23), has been shown to be im-
portant for apoptosis stimulated by a variety of signals (24, 25).
In addition, the Drosophila caspases DRONC and DRICE have
been shown to accumulate in large complexes reminiscent of
apoptosomes (26). However, cytochrome c release does not ap-
pear to occur in Drosophila cells (26, 27), and the role of
cytochrome c in Drosophila apoptosome formation is not clear.
Based on these and other results, it has been hypothesized
that a low level of constitutive caspase activity is present in
cells, and IAP proteins promote survival by suppressing ampli-
fication of the caspase cascade. Disruption of IAP-caspase in-
teractions thus provides an attractive approach to sensitizing
cells to death signals. However, an important unanswered
question is which IAP-caspase interactions are rate-limiting for
the survival of cells that normally live? We have used the RNAi
technique to dissect this pathway in insect cells. Our results
demonstrate that in unstimulated Drosophila S2 cells, DIAP1
is required to inhibit an activity dependent on DRONC and
DARK. Furthermore, DRONC is continuously processed in nor-
mal cells through a mechanism that requires DARK. However,
this initially processed form of DRONC does not normally
accumulate to significant levels because it is subject to degra-
dation by the proteasome. Removal of DIAP1 results in the
accumulation of processed DRONC, activation of the down-
stream caspase DRICE, and apoptosis.
EXPERIMENTAL PROCEDURES
Cell Lines—Spodoptera frugiperda Sf21 cells were maintained in
TC-100 medium (Invitrogen) supplemented with 10% tryptose broth
and 10% fetal bovine serum (FBS) (Invitrogen). Drosophila S2 cells
were maintained in Schneider’s medium (Invitrogen) supplemented
with 10% FBS.
RNAi Procedure—The RNAi technique was performed essentially as
described (28). Complementary RNA strands were transcribed in vitro
using the AmpliScribe kit (EpiCentre Technologies), mixed, and an-
nealed by heating to 65 °C for 15 min and then allowing to cool to room
temperature. For each gene, the following sequences were used to
generate dsRNA (based on the start codon of the coding sequence):
Sf-iap and CAT, all of the coding sequence; dark, nucleotides 1561–
2821; dronc, nucleotides 16–1160; diap1, nucleotides 406–1319; Sf-
actin, an unpublished 523 nucleotide partial cDNA sequence (obtained
from Dr. Lois Miller, University of Georgia). Sf21 or S2 cells were plated
overnight in 6-well plates at 5  105 or 1  106 cells per well, respec-
tively, in TC-100 medium supplemented with 10% FBS. The following
day, the medium was removed, and 80 g of dsRNA suspended in 1 ml
of TC-100 medium without FBS was added, followed by vigorous shak-
ing. After 4 (Sf21) or 5.5 h (S2), 1 ml of TC-100 medium with 20% FBS
was added to bring the final FBS concentration to 10%. Mock-treated
cells were subjected to the same procedure except that no RNA was
added.
To perform co-silencing, the RNAi procedure was performed as above
for the first gene. After 24 h cells were placed in TC-100 media without
FBS, and diap1 dsRNA was added as well as another dose of the first
dsRNA. Control cells were treated the same except cells received either
diap1 dsRNA alone or no dsRNA. In the cycloheximide experiment,
RNAi was performed on the indicated genes, and after 24 h 100 g/ml
of cycloheximide (Calbiochem) was added.
Apoptosis Assays—At various times after adding dsRNA, cell viabil-
ity was determined either by counting intact, non-blebbing cells in three
high power fields (Sf21 cells) or by resuspending the cells and counting
intact cells using a hemocytometer (S2 cells) and comparing to the
number of intact cells in the mock-treated control at 3 h. The experi-
ments were performed in duplicate three independent times.
DNA Laddering—To detect DNA laddering, cells were treated with
0.2 g/ml actinomycin D (Invitrogen) or dsRNA, and apoptotic bodies
and cells were collected 7 h later by centrifugation and lysed in 0.4 M
Tris, pH 7.5, 0.1% SDS, and 0.1 M EDTA. Following phenol/chloroform
extraction and ethanol precipitation, DNA was analyzed by 1% agarose
gel electrophoresis and visualized by ethidium bromide staining.
Transfection Assay—Plasmids (3 g) expressing green fluorescent
protein, baculovirus p35, or Op-IAP from a Drosophila heat shock
promoter were introduced into 5  105 Sf21 cells using lipid-mediated
transfection in TC-100 media without FBS. After 4 h, the lipid/DNA
mixture was replaced with TC-100 media containing 10% FBS. After an
additional 16 h, the cells were heat-shocked at 42 °C for 30 min, and 4 h
later dsRNA was added. For the caspase inhibitor experiment, S2 cells
were mock-treated or treated with diap1 dsRNA as above, except that
100 M Z-Val-Ala-DL-Asp-fluoromethyl ketone (Z-VAD-FMK, Alexis
Biochemicals) or 0.5% Me2SO (carrier control) was added with the
dsRNA. Inhibitor or carrier concentration was maintained when FBS
was added at 4 h. At 24 h after addition of dsRNA, cell viability was
determined as described above. The experiment was performed in
triplicate.
RT-PCR—Sf21 cells were treated with dsRNA as described above,
and at various times after treatment total RNA was isolated using
Trizol reagent (Invitrogen). Total RNA (3 g) was used in a reverse
transcriptase reaction with a gene-specific primer. From the resulting
50-l reaction, 2 l of cDNA was then used as a template in a PCR with
nested primers specific for the sequence of interest. In each case, at
least one of the primers used for PCR bound to nontranslated sequences
or to sequences outside of the region of the open reading frame used to
produce dsRNA. Dilutions (1:2 and 1:4) of cDNA were also used for PCR
to assess better the relative amounts of PCR product. The PCR products
were analyzed by agarose gel electrophoresis and ethidium bromide
staining.
Immunoblotting—S2 cells were treated with UV light by placing on
a transilluminator for 10 min, with 50 g/ml MG132 (Sigma), or with
dsRNA as above, except that each well contained 6  106 cells. At the
indicated times, cells were harvested and lysed in SDS-PAGE loading
buffer. Cell lysates were analyzed by immunoblotting using a mono-
clonal antibody against DIAP1 (18), polyclonal antisera raised against
a His6-tagged version of the DRONC p20 subunit (rabbit 51) (18), or
full-length DRICE, and SuperSignal chemiluminescent reagent
(Pierce).
RESULTS AND DISCUSSION
Silencing of iap Genes Induces Caspase-dependent Apoptosis
in Insect Cells—A homozygous loss of function mutation in
DIAP1 has been shown to result in widespread apoptosis dur-
ing Drosophila embryogenesis (15–17). To determine the effect
of depleting IAP proteins from cultured insect cells, two iap
genes from different insect species, Sf-iap from the lepidopt-
eran insect S. frugiperda (29) and diap1 from Drosophila mela-
nogaster, were silenced using RNAi. Within 4 h after addition
of Sf-iap dsRNA to Sf21 cells or diap1 dsRNA to S2 cells,
membrane blebbing was observed in both cell lines consistent
with apoptosis (Fig. 1, C and G). This morphology was indis-
tinguishable from that observed after treatment with actino-
mycin D, ultraviolet light, or cycloheximide, known inducers of
apoptosis in Sf21 and S2 cells. The blebbing intensified over time,
and by 24 h more than 99% of the cells had undergone apoptosis
(Fig. 1, D and H). Only very low background levels of apoptosis
were observed in mock-treated cells or cells treated with control
dsRNAs including dsRNA corresponding to the bacterial chlor-
amphenicol acetyltransferase (CAT) gene or Sf-actin (Fig. 1, A, B,
E, and F and data not shown). Apoptosis was also not observed
when either the plus or minus strands of Sf-iap RNA were added
separately to Sf21 cells (data not shown). These results are sim-
ilar to those recently reported by others (24–26, 30) using the
RNAi technique to silence diap1 in S2 cells.
DNA laddering was observed in Sf21 cells treated with Sf-iap
dsRNA similar to that seen following treatment with actino-
mycin D (31) (Fig. 2A), confirming that the cells died by apop-
tosis. Positive terminal deoxynucleotidyltransferase dUTP nick
end labeling staining indicated that S2 cells treated with diap1
dsRNA also underwent DNA fragmentation and apoptosis
(data not shown).
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To determine whether caspases were involved in the death
induced by iap silencing, we examined the effect of caspase
inhibitors on death induced by IAP depletion. Sf21 cells were
transfected with a plasmid vector expressing the baculovirus
caspase inhibitor P35, and then the cells were treated with
Sf-iap dsRNA. Transient expression of P35 inhibited the apo-
ptosis induced by the addition of Sf-iap dsRNA (Fig. 2B). In
addition, expression of the baculovirus iap gene Op-iap also
inhibited this apoptotic signal (Fig. 2B). In each case, the
amount of inhibition was similar to the average transfection
efficiency (54%), indicating that these anti-apoptotic genes
were highly effective at inhibiting this apoptotic signal. In S2
cells, apoptosis induced by loss of DIAP1 was inhibited by the
chemical caspase inhibitor Z-VAD-FMK (Fig. 2C), indicating
that loss of DIAP1 also resulted in caspase activation and
caspase-dependent apoptosis.
To confirm that the addition of dsRNA was in fact silencing
endogenous gene expression, the levels of mRNA for Sf-iap or
actin were examined by RT-PCR in Sf21 cells (Fig. 3A). Within
2 h after adding dsRNA, corresponding transcripts from either
gene were undetectable. There was no effect on the levels of
actin message when Sf-iap dsRNA was added or vice versa,
confirming the specificity of RNAi. In these experiments, the
dsRNA was added to cells in the absence of serum, and serum
was then added 4 h later. For unknown reasons, the RNAi
effect in Sf21 cells appeared to be reversed by the later addition
of serum. For both Sf-iap and actin, silenced message returned
to near normal levels after the addition of serum, and delaying
the addition of serum also delayed the reappearance of the
transcripts (Fig. 3 and data not shown). This reversal effect of
serum was not observed in S2 cells.
The levels of DIAP1 protein also decreased rapidly after
addition of diap1 dsRNA to S2 cells, with the protein becoming
undetectable by immunoblotting within 7.5 h (Fig. 3B). These
results are consistent with a short half-life for DIAP1 protein,
which has been shown to be 30–45 min in S2 cells following
cycloheximide treatment (18, 32).
DRONC and DARK Are Required for Apoptosis Stimulated
by Depletion of DIAP1—The fact that depletion of DIAP1 stim-
ulates caspase-dependent apoptosis suggests that DIAP1 nor-
mally promotes cell viability at least in part by inhibiting the
activity of one or more caspases. However, the caspase(s) in-
hibited by DIAP1 in vivo have not been identified. An obvious
candidate for a caspase targeted by DIAP1 was the caspase
DRONC, which is widely expressed in the developing Drosoph-
ila embryo and is required for developmentally programmed
embryonic cell death (33). In addition, DIAP1 binds to both the
pro-domain and core subunits of DRONC (14), and death in-
duced by ectopic DRONC expression in the fly and in yeast has
been shown to be inhibited by DIAP1 (13, 14). S2 cells were
treated with dronc dsRNA for 24 h, which reduced the amount
of full-length DRONC protein to a non-detectable level (see Fig.
5D). This treatment was followed by addition of diap1 dsRNA
to induce apoptosis. Remarkably, in cells that had been treated
with dronc dsRNA, death induced by silencing of diap1 was
largely suppressed, whereas cells that had been pre-treated
with control dsRNA underwent almost complete apoptosis (Fig.
4A). After 12 h, the surviving cells that were pre-treated with
FIG. 1. Silencing of endogenous iap genes induces apoptosis in
cultured insect cells. Sf21 (A–D) or S2 (E–H) cells were either un-
treated (A and E) or treated with either control chloramphenicol acetyl-
transferase (CAT) dsRNA (B and F) or dsRNA corresponding to Sf-iap
(C and D) or diap1 (G and H). Photographs were taken at 4 (C and G)
or 24 h (A, B, D–F, and H) after addition of dsRNA. Cell blebbing was
first detected at 3–4 h following addition of Sf-iap or diap1 dsRNA (C
and G), and nearly all cells were dead by 24 h (D and H). The magni-
fication for each photograph was 400 except (G), which was 1000.
FIG. 2. Cell death induced by iap silencing is due to apoptosis
and is caspase-dependent. A, DNA fragmentation was observed in
Sf21 cells treated 7 h with Sf-iap dsRNA or actinomycin D (ActD) but
not in cells treated with CAT dsRNA or mock-treated cells. B, Sf21 cells
were mock-transfected or transfected (trans.) with plasmids encoding
either control green fluorescent protein (GFP) or baculovirus P35 or
Op-IAP, and 24 h later Sf-iap dsRNA or control CAT dsRNA was added
as indicated below the graph. Cell viability was determined by apoptotic
morphology at 24 h after dsRNA addition, and the means  S.E. are
shown. The transfection process inhibited apoptosis stimulated by Sf-
iap RNAi to a slight degree for unknown reasons. C, S2 cells were either
mock-treated or treated with diap1 dsRNA, and at the same time either
0.5% Me2SO (DMSO, carrier control) or Z-VAD-FMK was added, and
cell viability was determined after 24 h. The means  S.E. are shown.
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dronc dsRNA began to divide, resulting in an apparent increase
in viability. Thus, death in these surviving cells appeared to be
completely inhibited, not just delayed, by depletion of DRONC.
In mammals, activation of caspase-9 requires dATP, cyto-
chrome c, and Apaf-1 (34). The homolog of Apaf-1 in Drosophila
is DARK (also known as Dapaf-1 or Hac-1) (21–23). In vitro
activation of DRONC is decreased in extracts made from mu-
tant fly embryos lacking DARK, indicating that DARK may
play a role in DRONC activation similar to that of Apaf-1 in
caspase-9 activation (33). In order to determine whether DARK
is also required for apoptosis stimulated by depletion of DIAP1,
S2 cells were treated with dark dsRNA, and 24 h later diap1
dsRNA was added to induce apoptosis. Co-silencing of dark and
diap1 also suppressed apoptosis induced by loss of DIAP1 and
resulted in even higher cell viability than cells co-silenced for
dronc and diap1 (Fig. 4A). Also, similar to dronc dsRNA-
treated cells, dark dsRNA-treated cells surviving after 12 h of
diap1 dsRNA treatment began to divide. Together, these data
indicate that an important function of DIAP1 in S2 cells is to
inhibit the activity of DRONC, and that DRONC activity is in
turn dependent on DARK.
S2 cells treated with cycloheximide undergo caspase-depend-
ent apoptosis within 3–4 h (18). Similar to diap1 RNAi, silenc-
ing dronc or dark prior to cycloheximide treatment dramati-
cally delayed apoptosis (Fig. 4B). Silencing dronc also strongly
inhibited apoptosis stimulated by UV light (data not shown).
These data are in agreement with the recent report (25) that
depletion of DARK by RNAi protected S2 cells from stress-
related apoptotic stimuli, including ultraviolet light and
cycloheximide.
The observation that depletion of dronc or dark did not
completely suppress apoptosis induced by a reduction in DIAP1
(Fig. 4A) may have been due to small amounts of DRONC or
DARK protein remaining after 24 h of dsRNA treatment. Al-
ternatively, there may be other apical caspases, such as
DREDD (35) or STRICA (36) that can become activated follow-
ing loss of DIAP1. This latter possibility is supported by the
greater protection seen with co-silencing of dark than with
dronc (Fig. 4A). Nevertheless, our results indicate that DRONC
appears to be the major apical caspase that is activated follow-
ing depletion of DIAP1, because the majority of cells are pro-
tected and continue dividing following diap1 and dronc RNAi.
DIAP1 Inhibits Excess Accumulation of Processed DRONC—
In addition to DRONC, another caspase, DRICE, is also known
to be activated in Drosophila embryos lacking DIAP1 (18).
Furthermore, immunodepletion of DRICE from apoptotic S2
cell lysates removed all of the detectable chromatin condensing
activity from the lysates, suggesting that DRICE plays a vital
role in apoptosis (37). These findings and our data showing the
requirement for DRONC and DARK in apoptosis stimulated by
depletion of DIAP1 or UV light led us to examine the activation
of DRONC and DRICE following treatment with these stimuli.
Lysates from S2 cells treated with diap1 dsRNA or UV light
were immunoblotted for DRONC and DRICE. Within 3 h after
treatment with either stimulus a processed form of DRONC,
hereafter referred to as Pr1, was detected (Fig. 5A). By 6 h, a
second, smaller processed form of DRONC, hereafter referred
to as Pr2, was also seen. Pr1 disappeared as Pr2 accumulated
over time, suggesting but not proving that Pr1 was being fur-
ther processed into Pr2. Full-length DRONC also disappeared
over time, although the decrease in full-length DRONC was
sometimes difficult to detect because it runs as a tight doublet
with a nonspecific background band (best seen in the right-
hand panel of Fig. 5A). On the other hand, DRICE processing
was not detected until 6 h after treatment with either stimulus
(Fig. 5B). The appearance of the Pr2 form of DRONC coincided
FIG. 3. Sf-iap and diap1 are specifi-
cally silenced by addition of the cor-
responding dsRNA. A, levels of Sf-iap
(left panel) or Sf-actin (right panel) mRNA
were determined by RT-PCR at 2-h inter-
vals following treatment with the dsRNAs
indicated on the left. The cDNA samples
were also diluted 2- or 4-fold prior to per-
forming RT-PCR to indicate relative tran-
script levels, and the dilution is shown
below each lane. B, the levels of DIAP1
protein were determined by immunoblot-
ting at the times shown following mock
treatment or treatment with diap1 or
CAT dsRNA. Coomassie Blue staining of
the same lysates verified equal protein
loading (data not shown).
FIG. 4. Co-silencing of DRONC or DARK suppresses apoptosis
induced by silencing of DIAP1 or by cycloheximide in S2 cells. A,
cells were treated with the indicated dsRNAs, and 24 h later diap1
dsRNA was added. Cell viability was assessed by apoptotic morphology
at various times after addition of diap1 dsRNA. B, cells were treated
with the indicated dsRNAs, and 24 h later the cells were treated with
cycloheximide, and cell viability was measured as above. In both A and
B, means  S.E. are shown.
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with the onset of DRICE processing, and thus may be a result
of cleavage of Pr1 by DRICE or another effector caspase. Both
Pr1 and Pr2, as well as full-length DRONC, were affinity-
labeled with biotinylated Z-VAD-fmk indicating that they are
enzymatically active processed forms of DRONC and not
merely inactive degradation products (data not shown).
Because of the length of their prodomains, it is widely as-
sumed that DRONC and DRICE are apical and effector
caspases, respectively. Our observation that DRONC is pro-
cessed earlier than DRICE following stimulation of apoptosis
supports this hypothesis. In order to determine whether proc-
essing of DRICE is dependent on DRONC, we examined
DRICE processing following depletion of DRONC. S2 cells
treated with dronc dsRNA for 24 h and then treated with diap1
dsRNA were immunoblotted for DRICE and showed almost no
DRICE processing (Fig. 5B). DRICE processing was also almost
completely inhibited when S2 cells were treated with UV light
after dronc RNAi (data not shown). In both cases, the cells
remained viable throughout the experiment. These results are
consistent with DRONC being an apical caspase that is re-
quired for processing of the effector caspase DRICE following
an apoptotic stimulus. In addition, these results also indicate
that in normal, living cells, DIAP1 promotes cell viability by
inhibiting DRONC activity and not that of DRICE, because
DRICE processing does not occur in the absence of active
DRONC.
Fly embryos lacking DIAP1 spontaneously undergo massive
apoptosis, as do S2 cells depleted of DIAP1 by RNAi. This
suggests that not only does DIAP1 inhibit DRONC activity, but
also that this activity is constitutively present in cells because
DIAP1 is required to prevent spontaneous apoptosis. Because
DIAP1 can bind to DRONC, this inhibition may be direct
and/or it may be due to DIAP1 acting as an E3 and causing the
degradation of DRONC by the proteasome. To determine
whether DRONC is targeted for proteasome degradation, S2
cells were treated with the proteasome inhibitor MG132 and
immunoblotted for DRONC. Interestingly, MG132-treated cells
consistently exhibited an accumulation of the Pr1 form of pro-
cessed DRONC (Fig. 5C), even though MG132 treatment itself
had no effect on cell viability. However, MG132 treatment did
not result in an increase in the levels of full-length DRONC
(Fig 5C). In addition, there was no further processing of
DRONC to the Pr2 form seen in cells undergoing apoptosis
induced by either UV treatment or diap1 dsRNA (compare Fig.
5, C and A). Thus, even in the absence of an apoptotic signal,
DRONC is continuously processed to the Pr1 form, and the Pr1
form is subject to proteasome-mediated degradation. Given the
fact that diap1 RNAi or UV light cause a rapid decrease in
DIAP1 levels, and the recent report (32) that DRONC is a
target for ubiquitination by DIAP1, it appears that DIAP1 is
required to prevent accumulation of the Pr1 processed form of
DRONC, probably by directing its ubiquitination.
These results also indicate that there are least two steps
involved in DRONC processing in vivo. We suggest that the
first cleavage, resulting in the Pr1 form, may be due to auto-
catalytic processing, whereas the second cleavage resulting in
Pr2 is specifically seen in dying cells and may be due to cleav-
age by an effector caspase such as DRICE. Although we do not
have direct evidence to support this conclusion, we believe it is
the simplest explanation for the observed results based the
following evidence. 1) The apparent molecular weight of Pr1 is
consistent with an in vitro autocatalytic cleavage event for
DRONC as demonstrated previously (13). DRONC was shown
previously to autoprocess itself in vitro after a glutamate res-
idue, Glu-352, and the apparent molecular weight of Pr1 is
similar to that expected if cleavage occurred at Glu-352 (40.3
FIG. 6. A model for how DIAP1 promotes Drosophila cell via-
bility. In normal living cells (upper panel), DRONC undergoes contin-
uous autoprocessing via a DARK-dependent mechanism. It is not clear
whether cytochrome c is involved in this process. DIAP1 promotes
degradation of autoprocessed DRONC via its E3 activity and may also
directly inhibit the enzymatic activity of autoprocessed DRONC. Upon
receiving a death stimulus (lower panel), DIAP1 levels decrease, and
autoprocessed DRONC levels increase. This leads to activation of effec-
tor caspases such as DRICE, which in turn further cleave DRONC and
other apoptotic substrates, resulting in apoptosis. The prodomain and
the large and small subunits of DRONC are shown, with the prodomain
shaded.
FIG. 5. DRONC undergoes continuous processing in S2 cells,
and DIAP1 is required to prevent accumulation of processed
DRONC. A, DRONC is processed into two forms, Pr1 and Pr2, following
treatment of S2 cells with UV light (left) or diap1 dsRNA (right). Cell
lysates were harvested at the times shown and immunoblotted for
DRONC protein. FL, full-length DRONC. The asterisk indicates a non-
specific background band. B, DRICE also undergoes processing follow-
ing apoptotic stimuli, but it is processed later than DRONC, and its
processing is dependent on DRONC. Cells were treated with UV light
(left) or diap1 dsRNA (middle), and lysates were harvested at the times
shown and immunoblotted for DRICE protein. In the right-hand panel,
S2 cells were treated with dronc dsRNA for 24 h to deplete DRONC
protein, and then diap1 dsRNA was added, and cells were harvested at
the times shown after diap1 dsRNA addition, and lysates were immu-
noblotted for DRICE. FL, full-length DRICE; Pr, processed DRICE. C,
proteasome inhibition results in accumulation of the Pr1 processed
form of DRONC. S2 cells were treated with MG132 and harvested at the
times shown. Lysates were immunoblotted for DRONC protein. D,
silencing of dark results in over-accumulation of full-length DRONC. S2
cells were treated with the indicated dsRNAs for 24 h, except diap1,
which was treated for 9 h. Cell lysates were harvested and immuno-
blotted for DRONC protein. A–D, the migration of molecular mass
markers is indicated to the left in kDa. In each case, similar results
were obtained in several independent experiments.
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kDa). Furthermore, the size of Pr2 is consistent with Pr1 being
further cleaved at the canonical caspase cleavage site (DEYD)
located at the boundary between the large and small subunits
at position 324 (expected size of 37.0 kDa). 2) The timing of the
appearance and disappearance of Pr1 and Pr2 suggests (but
does not prove) a precursor-product relationship between these
two forms of processed DRONC (Fig. 5A). 3) Because DRONC is
believed to be an apical caspase, it would be expected that the
initial cleavage event is autocatalytic. Pr1 is the first cleavage
product of DRONC observed following an apoptotic stimulus
and occurs before DRICE activation, whereas the appearance
of Pr2 correlates with DRICE activation.
DARK is required for efficient processing of DRONC in vitro
(33) and in the absence of DARK, apoptosis induced by either
diap1 dsRNA addition or cycloheximide treatment is largely
suppressed (Fig. 4). DARK may therefore play a role in the
continuous autoprocessing of DRONC. S2 cells were treated
with dark dsRNA and after 24 h immunoblotted for DRONC.
Remarkably, these cells showed an accumulation of full-length
DRONC (Fig. 5D), suggesting that DARK is indeed required for
the continuous autoprocessing of DRONC. These cells also
contained some of the Pr1 form of DRONC, which may have
been due to low levels of DARK remaining after RNAi or to
spontaneous DRONC dimerization and autoactivation that
may occur without the need for DARK when DRONC accumu-
lates to high levels, similar to the Apaf-1-independent activa-
tion observed when caspase-9 is present at higher than normal
concentrations (38). The presence of Pr1 DRONC in cells
treated with dronc dsRNA for 24 h (Fig. 5D) suggests that the
half-life of Pr1 in nonapoptotic cells may be relatively long
compared with the time required for autoprocessing of full-
length DRONC. If our hypothesis is correct that DRONC first
autoprocesses itself to Pr1 and only then is subject to protea-
some degradation, then it would be expected that full-length
DRONC would disappear faster than Pr1 following silencing of
dronc by RNAi. In addition, cells treated with dronc dsRNA are
not apoptotic, and thus Pr1 is not being further processed to
Pr2, possibly further lengthening Pr1 half-life.
Together these results provide evidence for a model (Fig. 6)
in which DRONC continuously undergoes processing to the Pr1
form in normal living cells, and this processed form, which we
suggest is due to autoprocessing, is continuously degraded via
the E3 activity of DIAP1. This initial processing step proceeds
through a mechanism that requires DARK, perhaps involving
apoptosome formation. In this model, DIAP1 is required to
inhibit the over-accumulation of Pr1 DRONC through its abil-
ity to act as an E3. However, once a death signal is received and
DIAP1 is removed, either through binding to apoptotic induc-
ers such as Hid, Reaper or Grim, or by degradation (18, 39–42),
this suppression is released and the Pr1 form of DRONC accu-
mulates, activating effector caspases such as DRICE which can
further cleave Pr1 DRONC to the Pr2 form as well as cleave
other apoptotic substrates, leading to apoptosis. This model
does not rule out the possibility that DIAP1 may also directly
inhibit the enzymatic activity of full-length and/or partially
processed DRONC. In fact, this possibility is suggested by the
fact that MG132 treatment resulted in an over-accumulation of
Pr1 DRONC, but these cells did not die (Fig. 5C).
Concluding Remarks—Prior to this work, the identity of the
caspase(s) that are normally inhibited by IAP proteins in any
living cells had not been determined. Our results indicate that
continuous expression of the short lived IAP protein DIAP1 is
required to inhibit the activity of the caspase DRONC and that
DRONC acts as an apical caspase in Drosophila S2 cells. Im-
portantly, our results showing induction of apoptosis in Sf21
cells following Sf-iap RNAi demonstrate that this pathway is
probably conserved in other insects as well.
Although it is widely assumed that DIAP1 inhibits caspase
activity in Drosophila, this is the first identification of a specific
caspase that must be inhibited by DIAP1 to promote cell sur-
vival. The activation of mammalian caspase-9 requires Apaf-1,
cytochrome c, and dATP (6). Our results suggest that the
Apaf-1 homolog DARK is also required for activation of
DRONC, as depletion of DARK caused an excess accumulation
of full-length DRONC, and silencing of dark prior to reducing
DIAP1 levels protected cells from apoptosis. However, unlike
caspase-9, DRONC appears to undergo continuous autopro-
cessing, even in normal living S2 cells. It is possible that in
insect cells, there is some level of constitutive apoptosome
formation that may not require cytochrome c but may involve
other factors. Recent data suggest that cytochrome c is not
required for apoptosome formation in Drosophila cells (25, 26),
although addition of cytochrome c further stimulated formation
of an apoptosome-like complex (26).
We found that treatment of cells with the proteasome inhib-
itor MG132 resulted in over-accumulation of the larger Pr1
processed form of DRONC, even though these cells remained
viable throughout the experiment. This result argues that this
processed form, which we suggest may result from autoprocess-
ing at Glu-352, is continuously produced in cells but is nor-
mally targeted for degradation by the proteasome. In contrast,
our data do not indicate that full-length DRONC is a protea-
some substrate in vivo, because there was no detectable excess
accumulation of full-length DRONC following treatment with
MG132. The involvement of DIAP1 in this degradation process
is supported by the increased levels of processed DRONC fol-
lowing silencing of diap1, and by the recent report (32) that
DIAP1 is capable of directing ubiquitination of DRONC.
In conclusion, the results of this study show that the apical
caspase DRONC is continuously processed in living Drosophila
cells, probably by an autocatalytic mechanism, and that DIAP1
is required to prevent accumulation of this processed form of
DRONC. This initial processing step is dependent on the
Apaf-1 homolog DARK and may occur by DARK promoting
DRONC dimerization, similar to the mechanism by which
Apaf-1 activates caspase-9. Removal of DIAP1 results in excess
accumulation of processed DRONC, activation of the down-
stream effector caspase DRICE, and apoptosis. Our results
thus have implications for therapeutic strategies aimed at dis-
rupting IAP function in mammalian cells, because they suggest
that targeting interactions between IAP proteins and apical
caspases are likely to be more effective at inducing cell death
than targeting interactions between IAP proteins and down-
stream effector caspases.
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